E-081
依替唑仑标准液 CRM 溶液
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H15ClN4S
化学文摘社编号:
分子量:
342.85
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3
SMILES string
CCC1=CC2=C(S1)N3C(CN=C2C4=CC=CC=C4Cl)=NN=C3C
InChI key
VMZUTJCNQWMAGF-UHFFFAOYSA-N
grade
certified reference material
form
liquid
feature
(Snap-N-Spike®)
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
drug control
Narcotic Licence Schedule B (Switzerland); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet, kontrollierte Droge in Deutschland
Quality Level
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
General description
经认证的溶液标准，可用于临床毒理学、尿液药物测试或法医分析中的LC/MS或GC/MS苯二氮卓测试方法。依替唑仑，商品名为Etilaam、Etizola或Depas，是一种苯二氮卓类似物，可用于失眠、焦虑或惊恐发作的短期治疗。依替唑仑也被作为化合致幻药销售，在欧洲和美国都有药物滥用的案例。
Biochem/physiol Actions
依替唑仑是一种噻吩并二氮杂卓抗焦虑药，与其他苯二氮卓类药物相比具有较低的依赖性。它与其他苯并二氮杂卓类药物的不同之处在于其分子具有噻吩环而不是苯环。它具有抗惊厥、镇静、抗焦虑、遗忘、催眠和肌肉松弛作用。它是通过作用于苯二氮卓受体而发挥作用的。它被用于治疗失眠、中度抑郁和社交焦虑症，并偶尔用于治疗眼睑痉挛和皮肤病变。
Legal Information
German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.
English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.
English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes
存储类别
3 - Flammable liquids
wgk
WGK 1
flash_point_f
49.5 °F
flash_point_c
9.7 °C
法规信息
监管及禁止进口产品
此项目有
Zenichiro Kato et al.
Pediatric emergency care, 23(7), 472-473 (2007-08-02)
Etizolam (ETZ) is an antidepressive thienodiazepine drug that is used worldwide. The most frequent adverse effects in adults are drowsiness and muscle weakness, and this can rarely cause paradoxical excitation; however, no information exists on intoxication in children. Furthermore, evidence
Maria Pia De Candia et al.
Clinical therapeutics, 31(12), 2851-2859 (2010-01-30)
Etizolam is an anxiolytic drug with a pharmacologic profile similar to that of the classic benzodiazepines. Neurochemical research suggests that etizolam may have selectivity for the subpopulation of Y-aminobutyric acid type A receptors associated with anxiety (ie, alpha1, beta2, gamma2).
Akira Watanabe et al.
Nihon Arukoru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence, 39(5), 482-487 (2004-12-03)
Drug dependence is a social problem of over the world and resistant to medical intervention by psychiatrist as well as general clinicians. In Japan, methamphetamine dependence is one of the most critical social problems, but opioid dependence is relatively rare.
Takeshi Terao et al.
Progress in neuro-psychopharmacology & biological psychiatry, 31(1), 295-296 (2006-08-19)
A 65-year-old female patient with major depressive disorder suffered from clonus, shivering and impaired visual acuity after 20 mg/day of paroxetine administration. The symptoms were initially regarded as further manifestations of her somatic symptoms of depression, and paroxetine was increased
Masahiro Hirase et al.
European journal of pharmacology, 597(1-3), 46-50 (2008-09-16)
The present study was performed to examine whether or not rebound insomnia is caused by an abrupt withdrawal of benzodiazepine hypnotics and tandospirone in rats. Etizolam and triazolam caused a significant shortening of sleep latency, increase in non-REM sleep time
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持